Nutex Health, Inc. (NUTX) Securities Class Action Lawsuit Update [October 6, 2025]

Introduction to Nutex Health, Inc. (NUTX) Securities Class Action Lawsuit

A securities fraud class action has been filed against Nutex Health, Inc. (NASDAQ: NTX) covering August 8, 2024 through August 14, 2025, both dates inclusive. Investors allege Nutex misrepresented the sustainability and legitimacy of arbitration-driven revenues tied to HaloMD, overstated progress remediating internal control weaknesses, and misclassified stock-based compensation obligations. The story shifted when a July 22, 2025 short-seller report alleged a coordinated scheme involving HaloMD, followed by Nutex's August 2025 announcements of a delayed quarterly filing and the need to restate prior accounting. As these events unfolded, Nutex's stock fell sharply on specific dates tied to the disclosures. According to the complaint, investors suffered significant losses when the market absorbed these revelations.

Nutex Health, Inc. (NUTX) Securities Lawsuit Case Details

Case Name: Bhagavan v. Nutex Health Inc., et al.

Case No.:  4:25-cv-03999

Jurisdiction: U.S. District Court, Southern District of Texas

Filed on: August 22, 2025

Nutex Health, Inc. (NUTX) Company Profile

Nutex is a physician-led healthcare services and operations company that went public via reverse merger in April 2022. It operates a hospital division of 24 facilities across 11 states, a population health management division, and real estate, and generally bills out-of-network with most net patient service revenue paid by third-party payors.

Nutex Health, Inc. (NUTX) Securities Lawsuit Class Period

August 8, 2024 – August 14, 2025, inclusive.

All persons and entities other than Defendants that purchased or otherwise acquired Nutex securities during the Class Period are within the alleged class.

Allegations in the Nutex Health, Inc. (NUTX) Securities Class Action Lawsuit

According to the complaint, the targets of the lawsuit are Nutex Health Inc. and three executives: CEO and Chairman Thomas T. Vo, CFO Jon C. Bates, and President and Director Warren Hosseinion. The case centers on allegedly misleading statements to investors about growth, the success of arbitration under the No Surprises Act (“NSA”), and the remediation of internal control weaknesses. The complaint also alleges misclassification and accounting issues related to stock-based compensation.

The narrative begins on August 8, 2024, when Bates stated in a press release that Nutex delivered 29% revenue growth, $12.0 million in Adjusted EBITDA attributable to Nutex, and a 150% increase in hospital division operating income to $22.8 million for Q2 2024, highlighting focus on top-line growth, cash flow, and profitability. That same day, Hosseinion said Nutex was "executing extremely well," driving "sustainable growth," accelerating cash flow, and strengthening its balance sheet, asserting confidence in steps for long-term success. On February 5, 2025, Vo issued a NSA arbitration update claiming proactive arbitration had yielded "positive results," securing "rightful payments" and positioning the company for continued success.

On March 31, 2025, Vo stated in a press release that Nutex delivered "healthy" year-end and Q4 results and that an arbitration initiative begun in July 2024 was generating higher reimbursement amounts per visit more in line with a fair market rate. Then on August 9, 2025, Vo told investors that arbitration offered "potential incremental value and revenue," citing public data showing providers prevailing 70% to 80% of the time, and framed arbitration as a tool to ensure fair treatment.

According to the complaint, Defendants' public statements were materially false and misleading, implying a different reality about Nutex's business, operations, and prospects. The complaint asserts HaloMD achieved lucrative arbitration outcomes for Nutex by coordinating a scheme to defraud insurers, rendering arbitration-driven revenues unsustainable to the extent they flowed from fraudulent conduct. It further alleges Nutex overstated remediation of material weaknesses in internal controls, could not effectively account for certain stock-based compensation obligations, and improperly classified those obligations as equity rather than liabilities—elevating the risk of delayed SEC filings and overstating the company's business and financial prospects.

The Truth Emerges

On July 22, 2025, Blue Orca Capital published a report alleging that HaloMD achieved dramatically lucrative results for clients like Nutex by executing a coordinated fraudulent scheme to steal millions from insurers on behalf of its healthcare billing clients. The report challenged Nutex's narrative about the legitimacy and sustainability of arbitration-driven revenues by alleging a coordinated scheme involving HaloMD.

Weeks later, on August 14, 2025, Nutex announced it would delay filing its Form 10-Q for the quarter ended June 30, 2025 due to non-cash accounting adjustments related to stock-based compensation obligations for under-construction and ramping hospitals; the company also provided preliminary results and announced a stock repurchase program of up to $25.0 million. Then on August 21, 2025, a Form 8-K disclosed that the Audit Committee concluded certain previously issued financial statements had treated non-cash obligations related to those hospitals as equity rather than liabilities and should be restated. These disclosures called into question prior assurances about internal control remediation and the Company's accounting for stock-based compensation obligations.

Market Reaction

According to the complaint, Nutex's stock declined following these disclosures. Following the Blue Orca report on July 22, 2025, Nutex's stock fell $11.18 per share, or 10.05%, to close at $100.01 that day. After Nutex failed to rebut the report's allegations, the stock dropped again on August 15, 2025—falling $18.22 per share, or 16.39%, to close at $92.91.

Next Steps

• Submissions for lead plaintiff are due October 21, 2025.
• The Court will issue its order for lead plaintiff and counsel in the weeks after submissions are due.
• The Court will then consider a motion for class certification; the complaint seeks certification under Rule 23.
• The Court will later consider a Motion to Dismiss.

To learn if you are eligible for recovery under the NUTX securities class action lawsuit, visit the case submission page here.

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.